CTA313 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

After 25 years under its founder, Toluna has a new CEO. Can Amy Fenton manage AI’s threat to market research?

Duralex rescue preserves 155 jobs as €16m plan targets lower energy costs

Editorial infographic showing the proposed combination of Panzani and Cerealis, highlighting an indicative €1.8 billion enterprise value, about €1 billion in combined annual revenue, nearly 1,800 employees, a 2025 revenue base of €620 million for Panzani and €400 million for Cerealis, and a European footprint spanning France, Portugal, Spain, the Netherlands and Central Europe.

Panzani and Cerealis plan €1.8bn European food group with €1bn in annual revenue

Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure

Read More

Pharma Industry News

A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy

Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.

bySoujanya Ravi

May 2, 2026

web analytics